Loading...
NASDAQ: INCY
Incyte Corporation
Healthcare · Biotechnology
●S&P 500 since 2017
Market Cap
$18.49B
52w High
$112.29
52w Low
$53.56
P/E
14.26
Volume
286.56K
Outstanding Shares
199.01M
Company profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
CEOWilliam J. Meury
SectorHealthcare
IndustryBiotechnology
Employees2,617
IPO dateNov 4, 1993
Valuation
Forward P/E—
EV/EBITDA9.23
Enterprise value$16.25B
Stock splits
Sep 1, 20002:1
Nov 10, 19972:1
Profitability & growth
Revenue growth27.84%
Gross margin91.8%▲0.41%vs FY2024
Operating margin26.35%▲1282.13%vs FY2024
ROE24.9%▲2531.99%vs FY2024
Analyst consensus
RatingBuy
Target price$108.90▲17.21%
24
Buy
18
Hold
2
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.57
$1.39
Q3FY25
ActualEst.
$2.26
$1.66
Q4FY25
ActualEst.
$1.80
$1.90
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.22B
$1.26B
Q3FY25
ActualEst.
$1.37B
$1.35B
Q4FY25
ActualEst.
$1.51B
$1.35B
Q1FY26
Next Est.
—